Current Opinion in Allergy and Clinical Immunology最新文献_第5页

Botulinum toxin for allergic rhinitis: a systematic review and meta-analysis of its therapeutic potential. 肉毒杆菌毒素治疗变应性鼻炎：其治疗潜力的系统回顾和荟萃分析。

IF 2.8 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-04-06 DOI: 10.1097/ACI.0000000000001150

Eric Tan Jin Wee, Yee Cheng Kueh, Norhafiza Mat Lazim, Baharudin Abdullah

{"title":"Botulinum toxin for allergic rhinitis: a systematic review and meta-analysis of its therapeutic potential.","authors":"Eric Tan Jin Wee, Yee Cheng Kueh, Norhafiza Mat Lazim, Baharudin Abdullah","doi":"10.1097/ACI.0000000000001150","DOIUrl":"10.1097/ACI.0000000000001150","url":null,"abstract":"Purpose of review: Botulinum toxin type A (BTX-A) is emerging as a promising intervention for refractory allergic rhinitis. This study evaluates its effectiveness in treating refractory allergic rhinitis.Recent findings: The primary outcome was total nasal symptom score (TNSS), while secondary outcomes included individual nasal symptom scores, quality of life (QOL), and adverse effects. Five trials involving 187 patients (mean age: 31.8 years) were included. BTX-A significantly improved TNSS at 4 weeks [SMD -2.07, 95% confidence interval (95% CI) -3.58 to -0.56; P < 0.001] and 12 weeks (SMD -2.42, 95% CI -4.22 to -0.62; P < 0.001). Neither comparison of BTX-A with triamcinolone injection nor oral cetirizine showed a significant difference in TNSS (SMD - 0.51, 95% CI -1.25 to 0.24; P = 0.18 and SMD 0.50, 95% CI -0.07 to 1.06; P = 0.08, respectively). In the BTX-A group, significant improvements were observed in rhinorrhea (SMD -2.18, 95% CI -3.74 to -0.62; P < 0.001), sneezing (SMD -1.88, 95% CI -2.60 to -1.15; P < 0.001), and itchiness (MD -1.57, 95% CI -2.45 to -0.69; P < 0.001) at 4 weeks, with these effects persisting up to 12 weeks. No serious adverse events occurred following BTX-A administration.Summary: BTX-A shows promise as an adjunctive therapy for refractory allergic rhinitis.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"176-183"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allergen-specific immunotherapy at earlier stages of allergic respiratory diseases: a change is in the air! 过敏性呼吸道疾病早期阶段的过敏原特异性免疫治疗：空气中有变化！

IF 2.8 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-04-29 DOI: 10.1097/ACI.0000000000001159

Carlo Lombardi, Giovanni Paoletti, Giovanni Passalacqua, Simona Barbaglia, Giorgio Walter Canonica

{"title":"Allergen-specific immunotherapy at earlier stages of allergic respiratory diseases: a change is in the air!","authors":"Carlo Lombardi, Giovanni Paoletti, Giovanni Passalacqua, Simona Barbaglia, Giorgio Walter Canonica","doi":"10.1097/ACI.0000000000001159","DOIUrl":"10.1097/ACI.0000000000001159","url":null,"abstract":"Purpose: This expert point of view discusses why allergen-specific immunotherapy (AIT) should be considered earlier in the management of allergic rhinitis and asthma, highlighting a shift from its traditional use as a last-line add-on therapy toward a more proactive, disease-modifying intervention in carefully selected patients.Recent findings: Large real-world datasets, including the REACT program and the EfficAPSI study, show that adding AIT to standard care in patients with allergic rhinitis, with or without mild-to-moderate asthma, is associated with sustained reductions in pharmacologic treatment needs, fewer severe asthma exacerbations, and lower healthcare utilization over long-term follow-up. Pediatric and adolescent analyses suggest that starting AIT earlier in life enhances these benefits, supporting the concept of a \"window of opportunity\" during which immune modulation may prevent or delay asthma onset and limit new sensitizations, in line with the notion of the allergic march.Summary: The accumulating real-world evidence that early AIT can alter the natural history of allergic airway disease provides a strong rationale to reposition AIT within clinical algorithms, moving it from a rescue option for pharmacologic failures to an earlier, integrated disease-modifying strategy. Earlier use of AIT, alongside optimized pharmacotherapy, may improve long-term control, reduce progression to severe asthma, with important implications for patients and health-care systems.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":"26 3","pages":"233-236"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Skin intervention for food allergy prevention: recent advances and clinical implications. 预防食物过敏的皮肤干预：最新进展和临床意义。

IF 2.8 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-04-06 DOI: 10.1097/ACI.0000000000001154

Kiwako Yamamoto-Hanada

{"title":"Skin intervention for food allergy prevention: recent advances and clinical implications.","authors":"Kiwako Yamamoto-Hanada","doi":"10.1097/ACI.0000000000001154","DOIUrl":"10.1097/ACI.0000000000001154","url":null,"abstract":"Purpose of review: Food allergy has increased globally, with infancy representing a critical window for prevention. Accumulating evidence has shifted attention toward the skin as a key route of allergen exposure, particularly in the context of atopic dermatitis. This review is timely given recent advances that have established the dual allergen exposure hypothesis as a clinical paradigm and growing interest in early skin-based interventions.Recent findings: Observational and interventional studies consistently identify early-onset atopic dermatitis as the strongest risk factor for food allergy. Current evidence does not support modification of routine skin cleansing practices for the purpose of food allergy prevention. Randomized controlled trials evaluating moisturizers have shown no convincing evidence that moisturizer use directly prevents food allergy. Any potential benefit appears limited to modulation of atopic dermatitis risk and may depend on formulation, timing, and target population. In contrast, early, sufficient, and anti-inflammatory treatment of atopic dermatitis - including treatment of nonlesional skin - has demonstrated the strong evidence for reducing egg allergy risk in recent randomized controlled trials.Summary: Skin-based interventions have a supportive but limited role in food allergy prevention. While moisturizers and skin cleansing alone are insufficient to prevent food allergy, early and adequate control of atopic dermatitis appears central to suppressing percutaneous sensitization. Effective prevention requires integrated, risk-stratified strategies combining optimal eczema management with appropriate food introduction and environmental considerations based on the dual allergy exposure theory. Further research is needed to establish well tolerated and sustainable prevention frameworks applicable to early life.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"214-220"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The interplay of chronic rhinitis and sleep-disordered breathing. 慢性鼻炎与睡眠呼吸障碍的相互作用。

IF 2.8 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-04-15 DOI: 10.1097/ACI.0000000000001153

Retno S Wardani, Natasha Supartono, Febriani Endiyarti

{"title":"The interplay of chronic rhinitis and sleep-disordered breathing.","authors":"Retno S Wardani, Natasha Supartono, Febriani Endiyarti","doi":"10.1097/ACI.0000000000001153","DOIUrl":"10.1097/ACI.0000000000001153","url":null,"abstract":"Purpose of review: This review examines how chronic rhinitis contributes to sleep-disordered breathing (SDB), shifting the focus from a localized nasal issue to a systemic sleep and respiratory disorder. It highlights inflammatory mechanisms that affect sleep differently from mechanical nasal obstruction, which worsens airway collapsibility.Recent findings: Evidence indicates that chronic rhinitis, regardless of allergy status, is associated with sleep fragmentation and lighter non-REM sleep, with some groups showing reduced REM sleep. Sleep improves, including partial REM restoration, after procedures such as functional endoscopic sinonasal surgery (including turbinoplasty and posterior nasal neurectomy) that reduce nasal resistance. NOSE scale scores, which reflect nasal obstruction severity, correlate with markers of respiratory instability, such as oxygen desaturation and epiglottic collapse, during sleep endoscopy. Excessive daytime sleepiness (ESS) reflects sleep fragmentation rather than specific respiratory events. Rhinitis-related sleep disruption involves oxidative stress and autonomic pathways beyond IgE-mediated inflammation, leading to hypoxia and systemic effects.Summary: Nasal airflow and inflammation are key determinants of sleep quality and respiratory stability. Using symptom-based tools with physiological assessments could better identify early and atypical SDB types. Treatments that open nasal passages and reduce inflammation may improve sleep and reduce intermittent hypoxia.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"184-188"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biosimilars in allergology: an outline in pediatric patients. 过敏症中的生物仿制药：儿科患者的大纲。

IF 2.8 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2026-05-26 DOI: 10.1097/ACI.0000000000001173

Giada Crescioli, Costanza Cacini, Francesco Catamerò, Simona Barni, Francesca Mori, Alfredo Vannacci, Mattia Giovannini

{"title":"Biosimilars in allergology: an outline in pediatric patients.","authors":"Giada Crescioli, Costanza Cacini, Francesco Catamerò, Simona Barni, Francesca Mori, Alfredo Vannacci, Mattia Giovannini","doi":"10.1097/ACI.0000000000001173","DOIUrl":"https://doi.org/10.1097/ACI.0000000000001173","url":null,"abstract":"Purpose of review: Biosimilars are increasingly shaping the management of pediatric allergic diseases and offering cost-effective alternatives to originator biology. This review summarizes the scientific and regulatory principles of biosimilars and examines the role of biosimilars in pediatric allergology, focusing on their clinical applications, opportunities, and challenges.Recent findings: Biosimilars were developed through a stepwise comparability process, including analytical, pharmacokinetic, pharmacodynamic, and clinical evaluations, to ensure equivalence with reference products. Among pediatric allergies, biologics targeting type 2 inflammation have significantly improved outcomes in several diseases, including asthma, atopic dermatitis, chronic spontaneous urticaria, and food allergies. Omalizumab is currently the only biologic drug with an approved biosimilar that has demonstrated comparable efficacy, safety, and immunogenicity, even after switching. However, concerns remain regarding limited availability of long-term pediatric data.Summary: Biosimilars represent a promising and sustainable opportunity to broaden access to advanced pediatric allergology therapies. Their integration into clinical practice, supported by growing evidence and appropriate clinical governance, has the potential to optimize treatment outcomes and improve long-term disease management. Further evidence on their risk-benefit profiles will help support their effective and informed use in the pediatric population.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148326520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence in allergen immunotherapy: toward a proactive and personalized management of allergic diseases. 过敏原免疫治疗中的人工智能：面向过敏性疾病的主动和个性化管理。

IF 2.6 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2026-05-26 DOI: 10.1097/ACI.0000000000001172

Sebastiano Gangemi, Luca Gammeri

{"title":"Artificial intelligence in allergen immunotherapy: toward a proactive and personalized management of allergic diseases.","authors":"Sebastiano Gangemi, Luca Gammeri","doi":"10.1097/ACI.0000000000001172","DOIUrl":"https://doi.org/10.1097/ACI.0000000000001172","url":null,"abstract":"Purpose of review: The management of immunoglobulin E (IgE)-mediated allergic diseases and allergen immunotherapy (AIT) is complicated by high interindividual variability and the unavailability of reliable predictive biomarkers. Given the complexity of the immune response underlying these processes, integrating artificial intelligence (AI) could revolutionize the clinical management of these patients.Recent findings: Recent literature highlights how machine learning (ML) can efficiently stratify patients by analyzing omics data and molecular sensitization profiles. Models such as long-term memory recurrent neural network and stochastic latent actor-critic enable the prediction of therapeutic adherence, while deep learning (DL) enables the integration of unstructured data from wearable sensors and environmental parameters for real-time monitoring. At the same time, federated learning (FL) is emerging as a crucial solution for multicenter research, ensuring data privacy in compliance with international standards and regulations. Conversely, although generative AI supports the synthesis of clinical records, recent studies highlight its limitations in terms of reliability for direct patient use.Summary: Integrating AI into AIT management could lead to even more efficient precision medicine, improving diagnostic accuracy and predicting therapeutic outcomes. However, while AI serves as a fundamental decision-making aid, specialist supervision remains essential to ensure patient safety and to interpret complex data.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk-based allergen labeling: reference doses, Japan's 10-ppm policy, and emerging challenges. 基于风险的过敏原标签：参考剂量、日本10ppm政策和新出现的挑战。

IF 2.6 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2026-04-28 DOI: 10.1097/ACI.0000000000001161

Tatsuki Fukuie, Hiroshi Akiyama

{"title":"Risk-based allergen labeling: reference doses, Japan's 10-ppm policy, and emerging challenges.","authors":"Tatsuki Fukuie, Hiroshi Akiyama","doi":"10.1097/ACI.0000000000001161","DOIUrl":"https://doi.org/10.1097/ACI.0000000000001161","url":null,"abstract":"Purpose of review: To summarize current advances in risk-based management of unintended food allergen presence, with a particular focus on Japan's unique 10-ppm labeling threshold and precautionary allergen labeling (PAL) prohibition, and to contextualize these within emerging international frameworks based on eliciting doses (EDs) and reference doses (RfDs).Recent findings: Quantitative risk assessment has shown that the aforementioned threshold offers a wide safety margin for most consumers allergic to egg, milk, and wheat, with estimated inadvertent exposures below the FAO/WHO RfDs. However, this threshold is associated with overly stringent requirements and a substantial management burden for some allergens, such as crustaceans. The FAO/WHO guidelines, Voluntary Incidental Trace Allergen Labeling (VITAL) 4.0, Codex, and regional initiatives are converging on ED-based RfDs alongside HACCP-based allergen management. In Japan, rapid shifts in nut consumption have altered allergy prevalence and ED distributions, highlighting the need for periodic threshold updates.Summary: Future allergen policy should integrate robust thresholds with realistic, HACCP-based allergen management in packaged foods and food-service settings, anticipate shifting dietary patterns, and support internationally harmonized, evidence-based PAL that enhances the safety and quality of life of food-allergic individuals.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New aspects of chronic beryllium disease. 慢性铍病的新认识。

IF 2.8 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2026-04-01 Epub Date: 2026-01-13 DOI: 10.1097/ACI.0000000000001140

Amanda Morgan, Maeve G MacMurdo

{"title":"New aspects of chronic beryllium disease.","authors":"Amanda Morgan, Maeve G MacMurdo","doi":"10.1097/ACI.0000000000001140","DOIUrl":"10.1097/ACI.0000000000001140","url":null,"abstract":"Purpose of review: Chronic beryllium disease (CBD) is a granulomatous lung disorder resulting from a cell-mediated immune response to beryllium exposure. Despite exposure regulations, new cases continue to emerge across both traditional and nontraditional occupational settings. In this review, we underscore ongoing diagnostic and preventive challenges, and strategies for screening and treatment of beryllium exposed patients.Recent findings: Recent updates to exposure standards and medical surveillance have broadened recognition of at-risk populations, including military personnel and construction workers. Advances in understanding the immunopathogenesis of CBD - particularly the central role of beryllium-specific CD4 + T cells and the strong genetic association with HLA-DPB1 alleles containing glutamic acid at position 69 (Glu69) - have provided critical insight into disease susceptibility and progression. However, gaps persist in access to testing, biomarker development, and understanding the natural history of sensitization and disease progression. Treatment remains centered on corticosteroids, with emerging but limited evidence for immunomodulatory and biologic therapies.Summary: Future directions include development of improved diagnostic biomarkers, refinement of screening protocols, and multicenter trials assessing steroid-sparing regimens. Coordinated translational and occupational research is essential to address persistent diagnostic uncertainty, reduce morbidity, and guide evidence-based management for affected individuals.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"100-106"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Occupational anaphylaxis: a comprehensive review. 职业性过敏反应：全面回顾。

IF 2.8 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2026-04-01 Epub Date: 2025-10-01 DOI: 10.1097/ACI.0000000000001116

Regina Treudler

{"title":"Occupational anaphylaxis: a comprehensive review.","authors":"Regina Treudler","doi":"10.1097/ACI.0000000000001116","DOIUrl":"10.1097/ACI.0000000000001116","url":null,"abstract":"Purpose of review: Occupational anaphylaxis refers to anaphylactic reactions triggered by substances encountered in the workplace. Management of occupational anaphylaxis includes emergency treatment, substitution of elicitors (triggers), technical and organizational measures as well as personal safety precautions. This review aims to provide a current overview on the development of the field with regard to definition of occupational anaphylaxis, risk factors, elicitors, clinical manifestations, diagnosis and management.Recent findings: Recent data from the Network for Online Registration of Anaphylaxis showed that 3.8% of cases were work-related. The vast majority of reported occupational anaphylaxis cases are caused by Hymenoptera venom followed by food allergens. Overall, occupational anaphylaxis is reported only rarely. Recently, an expert recommendation was published for defining diagnostic criteria for occupational anaphylaxis. These criteria consider if a worker was sensitized from work exposures and reacts at work or outside the workplace, or if sensitization is due to private exposure and reaction occurs at the workplace. Also, recent expert discussions of diagnosis, grading and management of anaphylaxis are presented.Summary: Occupational anaphylaxis seems to be rare, but underreporting and underdiagnosis due to lack of awareness and due to accepted diagnostic criteria is suspected.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"107-112"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145387658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Occupational hypersensitivity to cannabis. 职业性对大麻过敏。

IF 2.8 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2026-04-01 Epub Date: 2025-12-05 DOI: 10.1097/ACI.0000000000001137

Callan Krevanko, Coralynn Sack

{"title":"Occupational hypersensitivity to cannabis.","authors":"Callan Krevanko, Coralynn Sack","doi":"10.1097/ACI.0000000000001137","DOIUrl":"10.1097/ACI.0000000000001137","url":null,"abstract":"Purpose of review: The expansion of the legal cannabis market has driven rapid, exponential growth in its workforce. Emerging evidence suggests that occupational exposures during cannabis production contribute to respiratory and allergic disease in cannabis workers.Recent findings: There is a substantial burden of respiratory and allergic disease in cannabis production workers. Recent evaluations have demonstrated exposure to respiratory irritants and allergic sensitizers during cannabis production activities, though the cause of health symptoms among cannabis workers remains unknown. While some studies suggest that sensitization to cannabis plant allergens may drive disease, no epidemiological studies have quantitatively assessed the relationship between inhalation hazards and health outcomes in cannabis production workers.Summary: Research is critically needed on the etiology of work-related respiratory and allergic disease within the cannabis industry. Although the specific cause of reported health effects is uncertain, recent findings provide sufficient preliminary evidence to justify swift action to safeguard this rapidly growing workforce.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"95-99"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0